YUNUS EMRE ER

YUNUS EMRE ER


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MDMuhammed Değer
Muhammed Değer
TKTALAT KİLİC
TALAT KİLİC
ZUZeynep Ulutas
Zeynep Ulutas
MTMuhammed Said Tan
Muhammed Said Tan
HÖHatice Ödümlü
Hatice Ödümlü
OAOzan Akdağ
Ozan Akdağ
Background/Objectives: The acute complications of COVID-19 have been well characterized and are frequently associated with increased mortality. Although substantial knowledge regarding long COVID has accumulated since the beginning of the pandemic, important uncertainties remain regarding the long-term clinical, functional, radiological, and metabolic consequences of SARS-CoV-2 infection. Identification of post-COVID-19 complications is therefore essential for appropriate recognition and management. This study aimed to evaluate the long-term complications of COVID-19 at 3 and 9 months after infection. Methods: This prospective study was conducted at Inonu University Turgut Ozal Medical Center. Patients who presented with active post-COVID-19 complaints or for routine follow-up were enrolled. Participants were evaluated at the pulmonology outpatient clinic at 3 and 9 months. At each visit, persistent or new-onset symptoms were assessed, and pulmonary function tests (PFT), the six-minute walk test (6MWT), echocardiography (ECHO), and thoracic computed tomography (CT) were performed as clinically indicated. Patients were stratified into three groups according to the severity of acute illness: outpatient, ward-hospitalized, and ICU-hospitalized. Results: A total of 205 patients (120 male, 85 female) were included. Male patients had significantly higher rates of ward and ICU hospitalization than female patients (p = 0.006). At 9 months, 85.3% of patients had at least one persistent symptom; dyspnea (69.6%), cough (35.6%), and chest pain (32.5%) were the most common. FVC showed a statistically significant increase between months 3 and 9 (p = 0.014), and the 6MWT distance improved significantly (423.56 m vs. 464.10 m; p = 0.008). Ground-glass opacity, present in 90.2% of patients at admission, persisted in 44.3% at 9 months (p < 0.001). Reticular opacities, pleuroparenchymal bands, and mosaic perfusion patterns increased over time. ICU patients had significantly lower ejection fraction values compared with ward and outpatient groups at 9 months (p = 0.046). During follow-up, 13 patients developed pulmonary embolism and 7 developed new-onset diabetes mellitus. Conclusions: Despite the well-characterized acute phase, the long-term sequelae of COVID-19 remain a significant clinical challenge. Identification of late complications is critical for reducing morbidity and understanding the long-term societal and healthcare burden of the pandemic. Multidisciplinary long-term follow-up is warranted, particularly for patients who experienced severe acute illness.

12 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YEYUNUS EMRE ER
YUNUS EMRE ER
TKTALAT KİLİC
TALAT KİLİC
Background: Antifibrotic therapies slow disease progression in idiopathic pulmonary fibrosis (IPF) and are increasingly used in progressive pulmonary fibrosis (PPF), but adverse events may compromise treatment persistence. This study evaluated adverse events and treatment tolerability with pirfenidone and nintedanib in patients with IPF or PPF. Methods: This single-center ambidirectional study included 151 patients treated from January 2022 to June 2025 (120 retrospective; 31 prospective). Adverse events and treatment modifications were recorded. Results: Mean age was 67.5 ± 10.1 years; 64.9% were male, 68.9% had IPF, and 31.1% had PPF. At least one adverse event occurred in 56.3%, most commonly nausea (32.5%), vomiting (21.9%), and diarrhea (17.9%). Overall adverse-event rates were similar with pirfenidone and nintedanib (52.4% vs. 61.2%; p = 0.278). Diarrhea (6.0% vs. 32.8%; p < 0.001) and vomiting (15.5% vs. 29.9%; p = 0.034) were more frequent with nintedanib, whereas photosensitivity was more frequent with pirfenidone (16.7% vs. 1.5%; p = 0.002). Diabetes mellitus was associated with adverse events (74.1% vs. 52.4%; p = 0.040). Permanent treatment discontinuation occurred in 7.9%. Conclusions: Adverse events were common but generally manageable. The agents showed distinct adverse-event profiles, supporting early, individualized monitoring to acilitate treatment continuation.